For the fiscal year ending December 2025, consolidated revenue was JPY 18,521,234 thousand (a 60.3% decrease YoY), operating loss was JPY 5,013,195 thousand, and net loss attributable to owners of the parent was JPY 3,749,204 thousand. For the fiscal year ending December 2026, revenue is forecasted at JPY 32,000,000 thousand and operating income at JPY 4,600,000 thousand.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4587","jir_company_name":"PeptiDream Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-02-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4587-20260216-01.pdf","jir_short_summary":"For the fiscal year ending December 2025, consolidated revenue was JPY 18,521,234 thousand (a 60.3% decrease YoY), operating loss was JPY 5,013,195 thousand, and net loss attributable to owners of the parent was JPY 3,749,204 thousand. For the fiscal year ending December 2026, revenue is forecasted at JPY 32,000,000 thousand and operating income at JPY 4,600,000 thousand.","jir_summary":"### Performance Overview\nFor the fiscal year ending December 2025, consolidated revenue was JPY 18,521,234 thousand, a 60.3% decrease compared with the previous fiscal year, resulting in an operating loss of JPY 5,013,195 thousand. Net loss attributable to owners of the parent was JPY 3,749,204 thousand, representing a significant decline from the previous year's profit. The drug discovery development segment recorded revenue of JPY 2,793,300 thousand and a segment loss of JPY 5,379,999 thousand. Meanwhile, the radiopharmaceutical segment saw a slight increase in revenue to JPY 15,727,934 thousand and posted a segment profit of JPY 434,803 thousand. Cash and cash equivalents at the end of the period decreased by JPY 19,434,999 thousand compared to the previous year to JPY 28,682,933 thousand.\n\n### Outlook and Management Policy\nThe consolidated earnings guidance for the fiscal year ending December 2026 forecasts revenue of JPY 32,000,000 thousand, core operating income of JPY 4,600,000 thousand, operating income of JPY 4,600,000 thousand, and net income attributable to owners of the parent of JPY 3,000,000 thousand. Revenue is expected to increase 72.8% year over year, driven by existing joint research and development support fees, milestone income, PDPS\u00ae technology license revenues, upfront payments from new partnerships, and expansion of existing radiopharmaceutical products. Management policy focuses on expanding the clinical development pipeline, strategic concentration on five key areas, and growth into a global pharmaceutical company. Additionally, efforts are underway to strengthen internal controls and review governance structures, implementing preventive measures against the recurrence of inappropriate ordering and removal of reagents.","jir_financial_highlights":"Revenue: 18,521,234 thousand yen (60.3% decrease YoY)\nCore Operating Income: \u25b34,866,597 thousand yen (21,225,338 thousand yen in previous fiscal year)\nOperating Income: \u25b35,013,195 thousand yen (21,113,841 thousand yen in previous fiscal year)\nProfit Before Tax: \u25b35,312,129 thousand yen (20,888,805 thousand yen in previous fiscal year)\nNet Income Attributable to Owners of Parent: \u25b33,749,204 thousand yen (15,014,922 thousand yen in previous fiscal year)\nTotal Assets: 77,033,187 thousand yen (Decrease of 15,736,638 thousand yen YoY)\nTotal Liabilities: 25,504,924 thousand yen (Decrease of 10,502,603 thousand yen YoY)\nTotal Equity: 51,528,263 thousand yen (Decrease of 5,234,034 thousand yen YoY)\nNumber of Shares Outstanding at Period End (Common Stock): 130,010,400 shares (Unchanged from previous period)\nTreasury Shares: 796,435 shares (Increase YoY)\nCash and Cash Equivalents at Period End: 28,682,933 thousand yen (Decrease of 19,434,999 thousand yen YoY)\nConsolidated Earnings Guidance for FY December 2026 Revenue: 32,000,000 thousand yen (72.8% increase YoY)\nConsolidated Earnings Guidance for FY December 2026 Operating Income: 4,600,000 thousand yen (\u25b35,013,195 thousand yen in previous fiscal year)\nConsolidated Earnings Guidance for FY December 2026 Net Income Attributable to Owners of Parent: 3,000,000 thousand yen (\u25b33,749,204 thousand yen in previous fiscal year)","jir_category":"","jir_hashtags":"#PeptiDreamInc, #FinancialSummary, #financial_summary, #JapaneseStocks","jir_key_figures":"Revenue: 18,521,234 thousand yen (FY December 2025)\nOperating Income: \u25b35,013,195 thousand yen (FY December 2025)\nNet Income Attributable to Owners of Parent: \u25b33,749,204 thousand yen (FY December 2025)\nCash and Cash Equivalents at Period End: 28,682,933 thousand yen (FY December 2025)\nRevenue Forecast for FY December 2026: 32,000,000 thousand yen\nOperating Income Forecast for FY December 2026: 4,600,000 thousand yen\nNumber of Shares Outstanding at Period End (Common Stock): 130,010,400 shares","jir_meta_title":"PeptiDream Inc. Financial Summary for FY December 2025 Revenue JPY 18.5 Billion, Operating Loss JPY 5 Billion","jir_meta_description":"PeptiDream Inc.'s financial summary for the fiscal year ending December 2025. Revenue of JPY 18.52 billion, operating loss of JPY 5.01 billion, and net loss attributable to owners of parent of JPY 3.75 billion. Revenue of JPY 32 billion and operating income of JPY 4.6 billion forecasted for FY December 2026.","jir_og_title":"PeptiDream Announces Financial Summary for FY December 2025 Revenue JPY 18.5 Billion, Operating Loss JPY 5 Billion","jir_og_description":"PeptiDream Inc.'s financial summary for the fiscal year ending December 2025. Revenue decline noted, but recovery expected in 2026. Please refer to IR materials for details.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY December 2023\\\",\\\"FY December 2024\\\",\\\"FY December 2025\\\",\\\"FY December 2026 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[28712,46676,18521,32000],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY December 2023\\\",\\\"FY December 2024\\\",\\\"FY December 2025\\\",\\\"FY December 2026 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[6773,21113,-5013,4600],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY December 2023\\\",\\\"FY December 2024\\\",\\\"FY December 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[Unknown,15014,-3749],\\\"borderColor\\\":\\\"#3cba9f\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown (FY December 2025, Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Drug Discovery Development Business\\\",\\\"Radiopharmaceutical Business\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[2793,15727],\\\"backgroundColor\\\":[\\\"#ff6384\\\",\\\"#36a2eb\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"cash_flow_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Cash Flow Situation (2024 & 2025, Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Operating Activities\\\",\\\"Investing Activities\\\",\\\"Financing Activities\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"2024\\\",\\\"data\\\":[23845,8371,-2995],\\\"backgroundColor\\\":\\\"#3e95cd\\\"},{\\\"label\\\":\\\"2025\\\",\\\"data\\\":[-13277,-2054,-4058],\\\"backgroundColor\\\":\\\"#8e5ea2\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}]","ir_related_company":8926,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-29657","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n